Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Decreases By 12.0%
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the recipient of a large decrease in short interest in the month of December. As of December 29th, there was short interest totalling 4,199,485 shares, a decrease of 12.0% from the December 15th total of 4,773,699 shares. Currently, 2.7% of the company’s stock are short sold. Based on an average daily trading volume, of 539,880 shares, the short-interest ratio is currently 7.8 days.
Shares of Navidea Biopharmaceuticals (NAVB) opened at $0.39 on Thursday. Navidea Biopharmaceuticals has a 52 week low of $0.29 and a 52 week high of $0.85. The firm has a market cap of $61.50, a P/E ratio of -5.57 and a beta of -0.63.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 38.60% and a negative net margin of 688.85%. The business had revenue of $0.22 million for the quarter.
TRADEMARK VIOLATION NOTICE: “Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Decreases By 12.0%” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/11/short-interest-in-navidea-biopharmaceuticals-inc-navb-decreases-by-12-0.html.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.